| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ALT5 Sigma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$5.20 |
| 52 Week Low | US$0.24 |
| Beta | 2.16 |
| 11 Month Change | -36.13% |
| 3 Month Change | -64.12% |
| 1 Year Change | 65.99% |
| 33 Year Change | -77.41% |
| 5 Year Change | -57.51% |
| Change since IPO | -95.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5AR1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -13.5% | -0.2% | -0.07% |
| 1Y | 66.0% | -20.3% | -0.5% |
Return vs Industry: 5AR1 exceeded the German Pharmaceuticals industry which returned -20.3% over the past year.
Return vs Market: 5AR1 exceeded the German Market which returned -0.5% over the past year.
Price Volatility
| 5AR1 volatility | |
|---|---|
| 5AR1 Average Weekly Movement | 14.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5AR1's share price has been volatile over the past 3 months.
Volatility Over Time: 5AR1's weekly volatility has decreased from 25% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5 | Tony Isaac | alt5sigma.com |
ALT5 Sigma Corporation operates a next generation blockchain platform. It engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. The company’s products include ALT 5 Prime, an electronic over-the-counter trading platform to buy and sell digital assets; and ALT 5 Pay that enables payment processors to accept digital assets as payments, as well as make payment in digital assets.
ALT5 Sigma Corporation Fundamentals Summary
| 5AR1 fundamental statistics | |
|---|---|
| Market cap | €21.06m |
| Earnings (TTM) | -€17.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 5AR1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5AR1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.58m |
| Earnings | -US$18.58m |
Last Reported Earnings
Mar 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 38.1% |
How did 5AR1 perform over the long term?
See historical performance and comparison